Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Tumor Biology

• Publication date

  2014-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-014-1764-9PMID 24584817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Complete Remission Following Decitabine/Dendritic Cell Vaccine for Relapsed Neuroblastoma

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

  2012cited by this paper
• Cellular immunotherapy for soft tissue sarcomas.

  2012cited by this paper
• Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway

  2011cited by this paper
• Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.

  2011cited by this paper
• Immune-Based Therapies for Sarcoma

  2011cited by this paper
• MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing

  2011cited by this paper
• Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors

  2011cited by this paper
• Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Epigenetic Mechanisms Regulate MHC and Antigen Processing Molecules in Human Embryonic and Induced Pluripotent Stem Cells

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities

  2009cited by this paper
• Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

  2009cited by this paper
• Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.

  2008cited by this paper
• Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

  2007cited by this paper
• Expression of cancer-testis (CT) antigens in placenta.

  2007cited by this paper
• Cancer‐germline gene expression in pediatric solid tumors using quantitative real‐time PCR

  2007cited by this paper
• Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.

  2007cited by this paper
• Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

  2006cited by this paper
• Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy.

  2005cited by this paper
• MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma1

  2005cited by this paper
• CD4 cells can be more efficient at tumor rejection than CD8 cells.

  2005cited by this paper
• The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma.

  2004cited by this paper
• Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• The cancer/testis genes: review, standardization, and commentary.

  2004cited by this paper
• Immunomic analysis of human sarcoma

  2003cited by this paper
• Expression of cancer/testis (CT) antigens in lung cancer.

  2003cited by this paper
• Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.

  2002cited by this paper
• Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment

  2001cited by this paper
• Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7

  2001cited by this paper
• Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

  2001cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.

  1999cited by this paper
• Herpes Simplex Virus (HSV)-Mediated ICAM-1 Gene Transfer Abrogates Tumorigenicity and Induces Anti-Tumor Immunity

  1999cited by this paper
• The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid

  1999cited by this paper
• Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR).

  1999cited by this paper
• The intercellular adhesion molecule (ICAM) family of proteins

  1998cited by this paper
• High-throughput RT-PCR analysis of multiple transcripts using a microplate RNA isolation procedure.

  1997cited by this paper
• Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.

  1996cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.

  1995cited by this paper
• Recurrent chromosome alterations in non-small cell lung cancer.

  1994cited by this paper
• Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression.

  1994cited by this paper
• Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

  1994cited by this paper
• Regulation by retinoic acid of ICAM-1 expression on human tumor cell lines.

  1991cited by this paper

• Paediatric Solid Tumour Vaccines: Current Processes, Prevailing Challenges and Future Perspectives.

  2026cites this paper
• The DNA methylation landscape of musculoskeletal sarcomas

  2025cites this paper
• DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets

  2025cites this paper
• Evaluation and In Situ Library Expansion of Small Molecule MHC-I Inducers

  2025cites this paper
• Epigenetic Control of Alveolar Macrophages: Impact on Lung Health and Disease

  2025cites this paper
• T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

  2025cites this paper
• Decitabine conditioning improves NK cell maturation and limits CD8+ T cell terminal differentiation post-alloSCT in acute myeloid leukemia patients.

  2025cites this paper
• The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence

  2024cites this paper
• Progress Toward Epigenetic Targeted Therapies for Childhood Cancer

  2024cites this paper
• Getting the right combination to break the epigenetic code

  2024cites this paper
• Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy

  2024cites this paper
• Comparative responses to demethylating therapy in animal models of osteosarcoma

  2024cites this paper
• A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

  2023cites this paper
• Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy

  2023cites this paper
• Molecular predictors for decitabine efficacy in meningiomas – a pilot study

  2023cites this paper
• Mapping of DNA methylation-sensitive cellular processes in gingival and periodontal ligament fibroblasts in the context of periodontal tissue homeostasis

  2023cites this paper
• Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors

  2022cites this paper
• Targeted Epigenetic Interventions in Cancer with an Emphasis on Pediatric Malignancies

  2022cites this paper
• PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas

  2022cites this paper
• Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma

  2022cites this paper
• Interferon Gamma, MHC Class I Regulation and Immunotherapy

  2022cites this paper
• Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe

  2022cites this paper
• Immunological and functional aspects of MAGEA3 cancer/testis antigen.

  2021cites this paper
• Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia

  2021cites this paper
• MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It

  2021cites this paper
• Targeting the epigenetic regulation of antitumour immunity

  2020cites this paper
• The expression, modulation and use of cancer-testis antigens as potential biomarkers for cancer immunotherapy.

  2020cites this paper
• Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas

  2020cites this paper
• Cancer Testis Antigens in Sarcoma: Expression, Function and Immunotherapeutic Application.

  2020cites this paper
• Targeting the epigenetic regulation of antitumour immunity

  2020cites this paper
• OTT_A_217767 10903..10916

  2019cites this paper
• Immunological Effects of Epigenetic Modifiers

  2019cites this paper
• Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

  2019cites this paper
• DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses

  2019cites this paper
• CMAR_A_229768 10195..10203

  2019cites this paper
• Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

  2018cites this paper
• Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma

  2018cites this paper
• Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL–NKG2D Axis

  2018cites this paper
• Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

  2018cites this paper
• Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma.

  2017cites this paper
• Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

  2017cites this paper
• Expansion of cancer germline antigen–specific cytotoxic T lymphocytes for immunotherapy

  2017cites this paper
• From vision to reality: deploying the immune system for treatment of sarcoma.

  2017cites this paper
• Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine

  2016cites this paper
• Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.

  2016cites this paper
• Chapter 26 – Demethylating Agents

  2016cites this paper
• Improving cancer immunotherapy with DNA methyltransferase inhibitors

  2016cites this paper
• DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer

  2016cites this paper
• T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities

  2016cites this paper
• Current Immunotherapies for Sarcoma: Clinical Trials and Rationale

  2016cites this paper
• Decitabine: a promising epi-immunotherapeutic agent in solid tumors

  2015cites this paper
• Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

  2015cites this paper
• Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy

  2015cites this paper
• A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

  2015cites this paper
• Immunotherapy in Sarcoma: A Brief Review

  2014cites this paper
• Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

  2014cites this paper
• Advances in Therapy for Pediatric Sarcomas

  2014cites this paper
• Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report

  2014cites this paper